The increasingly competitive weight-loss therapeutic space was shaken up a bit on 29 September when structure-based drug design firm Structure Therapeutics, Inc. unveiled early data indicating that its oral GLP-1 receptor agonist can yield significant weight loss quickly and with a tolerability profile that should be competitive against injectable agents currently in great demand.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?